Hui Xiong
Capital Medical University(CN)Peking University(CN)University of California San Diego(US)Third Affiliated Hospital of Southern Medical University(CN)Laboratory of Molecular Genetics(PL)Buchang Pharma (China)(CN)Peking University First Hospital(CN)Beijing Children’s Hospital(CN)Second Affiliated Hospital of Zhejiang University(CN)Zhejiang Medicine (China)(CN)Southern Medical University(CN)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Neurogenetic and Muscular Disorders Research, Metabolism and Genetic Disorders, Mitochondrial Function and Pathology, RNA Research and Splicing
Most-Cited Works
- → Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls(2021)266 cited
- → Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial(2021)209 cited
- → Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go(2021)167 cited
- → Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial(2022)98 cited
- → Genotype/phenotype analysis in Chinese laminin‐α2 deficient congenital muscular dystrophy patients(2014)74 cited
- → Pediatric Autoimmune Encephalitis: Case Series From Two Chinese Tertiary Pediatric Neurology Centers(2019)61 cited